Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting

NEW YORK and CLEVELAND, May 17, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. ( ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening, rare, genetic diseases, announced today updated clinical data from the Phase 1/2 trial for EB-101, the company’s gene-corrected skin graft cell therapy for patients suffering from recessive dystrophic epidermolysis bullosa (RDEB).

The results demonstrate robust and durable clinical effects achieved throughout various timepoints post-administration. Results were reported today during the ASGCT (American Society for Gene and Cell Therapy) 21st Annual Meeting in Chicago, IL.